R

Redx Pharma PLC
LSE:REDX

Watchlist Manager
Redx Pharma PLC
LSE:REDX
Watchlist
Price: 15 GBX 31.58% Market Closed
Market Cap: 50.2m GBX

Relative Value

There is not enough data to reliably calculate the relative value of REDX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

REDX Relative Value
Base Case
Not Available
R
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
12
Median 5Y
12
Industry
2.5
Forward
3.6
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-7.9
Industry
21.6
Forward
-2.4
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-3
Industry
16.7
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-2.1
Industry
24
vs History
vs Industry
Median 3Y
15
Median 5Y
15
Industry
2.2
vs History
vs Industry
Median 3Y
11.7
Median 5Y
11.7
Industry
2.7
Forward
3.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.3
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-7.2
Industry
12.9
Forward
-2.1
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-7
Industry
16.3
Forward
-2
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-2.5
Industry
15.2
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-2.5
Industry
17.7
vs History
vs Industry
Median 3Y
17.1
Median 5Y
24.3
Industry
1.9

Multiples Across Competitors

REDX Competitors Multiples
Redx Pharma PLC Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Redx Pharma PLC
LSE:REDX
50.2m GBP 12 -1.5 -1.6 -1.6
US
Eli Lilly and Co
NYSE:LLY
731.4B USD 14.9 65.9 35.4 38.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.3B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.3 18.4 12.7 14.6
CH
Roche Holding AG
SIX:ROG
202.8B CHF 3.4 24.5 9.2 10.8
CH
Novartis AG
SIX:NOVN
188.2B CHF 4.4 18.3 10.8 14.4
UK
AstraZeneca PLC
LSE:AZN
162.7B GBP 4 28.1 130.7 197.1
US
Merck & Co Inc
NYSE:MRK
205.1B USD 3.2 11.8 8.7 10.6
IE
Endo International PLC
LSE:0Y5F
183.8B USD 79.3 -62.9 292.4 733.2
US
Pfizer Inc
NYSE:PFE
139.9B USD 2.2 17.7 7.6 10.7
P/E Multiple
Earnings Growth PEG
UK
R
Redx Pharma PLC
LSE:REDX
Average P/E: 25.2
Negative Multiple: -1.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
65.9
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.4
18%
1
CH
Roche Holding AG
SIX:ROG
24.5
32%
0.8
CH
Novartis AG
SIX:NOVN
18.3
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.1
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.8
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -62.9 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.7
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
R
Redx Pharma PLC
LSE:REDX
Average EV/EBITDA: 436.6
Negative Multiple: -1.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.4
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
13%
1
CH
Roche Holding AG
SIX:ROG
9.2
5%
1.8
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.7
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
292.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
R
Redx Pharma PLC
LSE:REDX
Average EV/EBIT: 1 874.9
Negative Multiple: -1.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.7
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
10.8
6%
1.8
CH
Novartis AG
SIX:NOVN
14.4
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.1
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.6
11%
1
IE
E
Endo International PLC
LSE:0Y5F
733.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.7
10%
1.1